Improve Medical Instruments Co., Ltd. Class A

Improve Medical Instruments Co., Ltd. Class A

SSZSE:300030
6.27
CNY
-0.76
(-10.81%)
0.04EPS
228.84P/E
2.14BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.38
1.57
1.78
1.7
1.97
1.77
1.77
3
2.58
2.29
2.04
1.87
1.67
1.62
Basic EPS, GAAP
0.16
0.18
0.13
0.1
0.04
-0.44
0.08
0.53
0.06
-0.64
-0.2
-0.38
0.05
0.03
Free Cash Flow per Basic Share
-0.06
-0.65
-0.34
-0.01
0.17
0.02
-0.02
0.28
0.33
-0.05
0.11
0.1
0.3
- -
Dividend per Share
0.03
0.03
0.06
0.07
0.05
0.1
0.08
0.09
0.1
0.12
0.05
0.04
0.02
0.01
Book Value per Share
2.31
2.47
2.98
3.06
3.09
2.62
2.69
3.24
3.23
2.54
2.34
1.96
2.01
2.07
Tangible Book Value per Share
1.98
2.08
2.14
2.2
2.14
1.95
2.02
2.63
2.6
2.22
2.13
1.81
1.9
1.97
Basic Weighted Avg Shares
288
295
306
305
279
311
325
307
309
310
316
310
291
309
Sales/Revenue/Turnover
397
462
545
517
550
550
575
919
800
711
645
581
486
500
Operating Margin (%)
10.57
11.1
9
7.65
10.88
2.2
8.17
18.67
7.81
-2.27
-0.57
4.18
8.61
13.47
Depreciation Expense
22
25
33
39
38
38
36
37
53
47
45
40
34
- -
Net Income, GAAP
46
53
40
30
11
-137
26
163
19
-198
-63
-118
15
9
Effective Tax Rate (%)
13.77
13.94
17.07
24.72
51.29
- -
29.36
1.07
17.08
- -
- -
- -
33.03
47.92
Profit Margin (%)
11.62
11.49
7.3
5.89
2.03
-24.87
4.53
17.68
2.32
-27.9
-9.8
-20.28
2.99
1.87
Working Capital
456
259
231
183
457
404
121
390
166
80
61
77
105
130
LT Debt
- -
20
74
59
438
324
26
226
46
32
11
54
25
18
Total Equity
773
782
930
954
964
814
832
1,003
1,030
821
762
644
655
668
Return on Invested Capital (%)
5.26
5.46
2.95
1.46
0.57
- -
2.05
11.91
1.65
- -
- -
- -
1.59
- -
Return on Capital (%)
5.57
6.03
4.37
3.36
1.88
- -
3.57
13.44
2.54
- -
- -
- -
1.92
- -
Return on Common Equity (%)
6.93
7.5
4.83
3.27
1.18
-15.51
3.18
17.77
1.86
-22.22
-8.39
-17.73
2.37
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
112
80
42
LT Borrowings
22
20
17
LT Finance Leases
- -
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
309
309
309
Market Capitalization
2,371
1,796
2,140

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
430
406
346
Cash, Cash Equivalents & STI
168
150
137
Accounts Receivable, Net
119
110
113
Inventories
91
94
76
Total Current Liabilities
296
269
217
Payables & Accruals
- -
- -
- -
ST Debt
112
80
42
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-2.77%
-7.7%
1.74%
Free Cash Flow
-388.28%
-52.75%
180.72%
Net Income, GAAP
-235.78%
-270.08%
-112.32%
Sales/Revenue/Turnover
0.6%
-11.92%
-16.35%
Total Cash Common Dividend
-0.45%
-19.9%
-54.07%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
141
152
128
160
581
2025
116
115
- -
137
486
2026
95
120
148
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.01
-0.01
-0.12
-0.24
-0.38
2025
0.03
0.02
- -
-0.03
0.05
2026
0.07
0.03
-0.04
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.01
0.01
0.04
2025
0.01
- -
- -
- -
0.02
2026
- -
- -
- -
- -
- -

Company Description

CEO
Guang Cheng Jiang
Full Time Employees
632
Sector
Health technology
Industry
Medical specialties
Address
No. 102, Kaiyuan Avenue Zhuhai GD China 510530
IPO Date
Dec 28, 2009
Business
Improve Medical Instruments Co., Ltd. delivers advanced solutions, specialized products, and comprehensive services for clinical diagnostics and patient care settings both in China and across international markets. The company’s extensive offerings feature prominent items like the IMPROVACUTER vacuum blood collection systems, IMPROMINI capillary blood collection devices, IMPROSWAB microbial transport systems, and IMPRONURSE infusion and syringe pumps. Furthermore, they provide LONGX urine analysis systems, a variety of in-vitro diagnostic reagents, and blood collection needles. The portfolio extends to include pulsewave blood pressure monitors, viscoelastic thrombosis analysis systems, sophisticated feces analysis systems, intelligent equipment for blood collection tube preparation, intuitive graphic user interfaces, automated sorting machinery, ergonomic multi-function blood collection tables, smart queuing systems, automated urine collection tube preparation systems, and consumable labels. Established in 1996 and based in Guangzhou, China, the firm maintains its focus on innovation within the medical instrumentation sector.